Skip to main content
Evogene Ltd. logo

Evogene Ltd. — Investor Relations & Filings

Ticker · EVGN ISIN · IL0011050551 TA Professional, scientific and technical activities
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country IL Israel
Listing TA EVGN

About Evogene Ltd.

https://evogene.com/

Evogene Ltd. is a computational biology company that leverages artificial intelligence and big data to discover and develop novel life-science products. The company's proprietary Computational Predictive Biology (CPB) platform is designed to optimize the probability of success and reduce the time and cost of development. Evogene operates in the fields of human health, agriculture, and industrial applications. Its technology is organized into three AI-driven engines tailored for specific product types: MicroBoost AI for microbe-based products, ChemPass AI for small molecule-based products, and GeneRator AI for products based on genetic elements. The company's business model involves supporting subsidiary companies that focus on specific commercial fields, utilizing Evogene's technology to bring innovative products to market.

Recent filings

Filing Released Lang Actions
First Quarter 2026 Financial Results Release
Regulatory Filings
2026-05-07 Hebrew (modern)
First Quarter 2026 Financial Results Release
Regulatory Filings
2026-05-07 Hebrew (modern)
Other Report or Announcement
Director's Dealing Classification · 1% confidence The document is a Form 3 filed with the U.S. SEC under Section 16(a), disclosing the beneficial ownership of securities by an insider (Polina Ravzin, VP Finance and director). It reports direct and indirect holdings and option grants, which matches the definition of a Director’s Dealing filing (insider personal transaction disclosures).
2026-04-10 English
Other Report or Announcement
Director's Dealing Classification · 1% confidence The document is an initial statement of beneficial ownership (Form 3) filed by a foreign private issuer regarding insider share holdings, which falls under director/executive share transactions. This matches the definition of Director's Dealing (DIRS).
2026-04-10 English
Other Report or Announcement
Regulatory Filings Classification · 1% confidence The document is a Form 6-K filed with the U.S. SEC by Evogene Ltd. disclosing a Nasdaq minimum bid price deficiency letter and attaching a press release. It is a regulatory announcement rather than an earnings release, management change, dividend notice, delisting, or capital financing update. It is not the publication of a separate report but the actual SEC filing itself. None of the specific categories (e.g., earnings release, board changes, M&A, etc.) fit. Therefore, it falls under the catch-all “Regulatory Filings” category (RNS).
2026-04-03 English
Other Report or Announcement
Report Publication Announcement Classification · 1% confidence The document is only ~1,900 characters and serves as a brief announcement indicating that a report “is attached” (6K_bid_price_isa.pdf) regarding Evogene’s receipt of a Nasdaq minimum bid price notification. It does not contain the substantive report itself but rather informs investors that the report will be published or is available. This matches the Report Publication Announcement (RPA) category under the “menu vs meal” rule.
2026-04-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.